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Abstract
This study was designed to evaluate irinotecan (CPT-
11) disposition and pharmacodynamics in the presence and
absence of the broad-spectrum antibiotic neomycin. Seven
evaluable cancer patients experiencing diarrhea graded >2
after receiving CPT-11 alone (350 mg/m2 i.v. once every 3
weeks) received the same dose combined with oral neomycin
at 1000 mg three times per day (days 22 to 5) in the second
course. Neomycin had no effect on the systemic exposure of
CPT-11 and its major metabolites (P > 0.22). However, it
changed fecal b-glucuronidase activity from 7.03 6 1.76
mg/h/mg (phenolphthalein assay) to undetectable levels and
decreased fecal concentrations of the pharmacologically ac-
tive metabolite SN-38. Although neomycin had no signifi-
cant effect on hematological toxicity (P > 0.05), diarrhea
ameliorated in six of seven patients (P 5 0.033). Our find-
ings indicate that bacterial b-glucuronidase plays a crucial
role in CPT-11-induced diarrhea without affecting entero-
cycling and systemic SN-38 levels.
Introduction
CPT-113 is an inhibitor of topoisomerase I, an enzyme
responsible for variations in the topological form of DNA dur-
ing replication and transcription. Unlike other clinically used
camptothecin analogues, CPT-11 is a prodrug with very little
inherent antitumor activity that needs to be hydrolyzed by a
carboxylesterase to form the active metabolite SN-38 (Ref. 1;
Fig. 1). SN-38 in its turn is efficiently metabolized by UDP
glucuronosyltransferase 1A1 to form the inactive SN-38G (2).
Myelosuppression and diarrhea are among the most com-
mon side effects of CPT-11 (3), regardless of the schedule of
administration. Delayed-type diarrhea is defined as diarrhea
occurring .24 h after CPT-11 administration and contrasts with
the early-onset diarrhea that is acetylcholine mediated and can
be prevented by atropine (4). CPT-11-induced delayed-type
diarrhea has been reported to be severe (NCI-CTC grade 3–4) in
;25% of the patients (5). Moreover, even less severe diarrhea
might influence continuation of therapy. The median onset of
delayed-type diarrhea is day 5 after start of CPT-11 administra-
tion, and the median duration is 5 days. Delayed-type diarrhea
necessitated hospitalization in 9% of the cycles for i.v. rehydra-
tion. There is no generally accepted prophylactic treatment for
the delayed-type diarrhea. However, once diarrhea has occurred,
a high-dose loperamide regimen renders this side effect man-
ageable (6).
Many pharmacokinetic analyses in humans have been per-
formed to predict the incidence of delayed-type diarrhea, with
conflicting results. Some studies reported a correlation between
late-onset diarrhea and biliary secretion of the active metabolite
SN-38, as determined by the extent of SN-38G measured in
plasma (7). Recently, it was suggested from animal models that
b-glucuronidases produced by microflora in the large bowel
may play a major role in the development of CPT-11-induced
diarrhea by mediating hydrolysis of SN-38G to form the active
SN-38 (8). Data obtained in rats have indicated that penicillin
combined with streptomycin inhibited the b-glucuronidase ac-
tivity from the intestinal microflora, thereby decreasing the
luminal SN-38 concentration and subsequently reducing cecal
damage and ameliorating diarrhea. This antibiotic treatment did
not alter plasma pharmacokinetics of CPT-11 or SN-38 in the rat
model (9).
Theoretically, modulation of CPT-11-induced delayed-
type diarrhea in humans by coadministration of the poorly
absorbed aminoglycoside antibiotic neomycin (10) could be
advantageous. In this study, we assessed the influence of coad-
ministration of oral neomycin on the metabolic disposition and
pharmacodynamics of CPT-11 in a group of cancer patients
using a cross-over design.
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Patients and Methods
Patients and Treatment. Patients with a histologically
or cytologically confirmed diagnosis of colorectal cancer refrac-
tory to therapy with 5-fluorouracil were eligible for the present
study. Additional eligibility criteria included: ages between 18
and 70 years; Eastern Cooperative Oncology Group perform-
ance status #1; no previous treatment with antineoplastic agents
for at least 4 weeks (or 6 weeks in case of nitrosoureas or
mitomycin C); no prior treatment with CPT-11 or other topoi-
somerase I inhibitors; adequate hematopoietic (WBCs $3.0 3
109/liter, absolute neutrophil counts $2.0 3 109/liter, and plate-
let counts $100 3 109/liter), renal (serum creatinine #135 mM
or creatinine clearance $60 ml/min), and hepatic function (total
serum bilirubin #1.253 upper normal limit, and ASAT and
ALAT levels #3.0 3 upper normal limits); and no unresolved
bowel obstruction or chronic colic diarrhea. The clinical proto-
col was approved by the Rotterdam Cancer Institute Ethics
Board, and all patients signed informed consent before study
entry.
Vials that contained 40 or 100 mg of CPT-11 (as a hydro-
chloride trihydrate form) formulated as a concentrated sterile
solution (active drug concentration, 20 mg/ml) in d-sorbitol and
a lactic acid-sodium hydroxide buffer system of pH 3.5–4.5
were provided by Aventis (Hoevelaken, the Netherlands). The
CPT-11 dose of 350 mg/m2 was administered once every 3
weeks as a 90-min i.v. infusion, after dilution of the pharma-
ceutical preparation in 250 ml of isotonic sodium chloride. In all
patients, premedication consisted of 8 mg of ondansetron i.v.
combined with 10 mg of dexamethasone i.v., both administered
30 min before the start of CPT-11 infusion. Delayed-type diar-
rhea (in the first course) was treated with 4 mg of loperamide,
followed by 2 mg every 2 h for a 12-h time period after the last
stool. In case the patient developed diarrhea of grade 2 or higher
in the first course despite loperamide therapy, neomycin (1000
mg daily 3 3) was administered p.o. at days 22 to 5 relative to
the second CPT-11 administration. All toxicities were graded
according to the NCI-CTC.
Sample Collection and Analysis. Blood samples for
pharmacokinetic analysis were drawn during the first course and
in case of neomycin cotreatment during the second course as
Fig. 1 Schematic representation of CPT-11 metabolism and enterohepatic recirculation. CE, carboxylesterase; hCE1/2, human carboxylesterase
isoforms 1 and 2; UGT1A1/7, UDP glucuronosyltransferase isoforms 1A1 and 1A7; CYP3A4/5, cytochrome P450 isoforms 3A4 and 3A5; APC,
7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin; NPC, 7-ethyl-10-[4-N-(1-piperidino)-1-amino]carbonyloxycampto-
thecin. * indicates the sites of drug measurement.
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well, from a vein in the arm opposite to that used for drug
infusion and collected in 10-ml glass tubes containing lithium
heparin as anticoagulant. Samples were obtained at the follow-
ing time points: before drug administration; at 0.5, 1, and 1.5 h
during infusion; and 0.17, 0.33, 0.5, 1, 1.5, 2, 4, 5, 8.5, 24, 32,
48, 56, 196, 360, and 504 h after the end of infusion. Blood was
immediately processed to plasma by centrifugation for 5 min at
2500 rpm (4°C), which was then stored at 280°C until the time
of analysis by high-performance liquid chromatography as de-
scribed (11, 12). A pretreatment feces sample was collected
from all patients 1 day prior to drug administration in a poly-
styrene container and stored immediately at 280°C. Similarly,
stool collections were obtained separately for the duration of
hospitalization (;60 h). After thawing, these samples were
homogenized individually on ice (at 0°C) to prevent enzyme
degradation in 1 or 2 volumes of a 0.1-M sodium acetate buffer
(pH 7.0), depending on the water content of the sample, using an
Ultra-Turrax T25 homogenizer (IKA-Labortechnik, Dottingen,
Germany). The homogenates were centrifuged for 5 min at
15,000 rpm, and the clear supernatants were diluted 1-fold with
50% glycerol in water (v/v). The dilutions were stored at 280°C
until analysis for b-glucuronidase activity by a miniaturized
colorimetric assay using phenolphthalein glucuronic acid as an
artificial substrate (13). Urine samples were also collected from
each patient during the second treatment course to evaluate the
extent of neomycin absorption, as measured by a quantitative
cylinder-plate microbial assay (lower limit of detection, 1.0
mg/ml).
Feces cultures within 2 days prior to therapy were taken to
determine the presence of neomycin-resistant microorganism.
During the second course, feces cultures were taken daily from
days 23 to 3 after CPT-11 infusion and analyzed for the
presence of neomycin-resistant microorganism and/or over-
growth with Staphylococci in addition to microorganisms (Sal-
monella, Shigella, Yersinia, and Campylobacter species) and
toxins (Clostridium species) that could provoke diarrhea.
Pharmacological Analysis. Individual plasma concen-
trations of CPT-11 and its metabolites were fit to a three-
compartment model using the Siphar version 4.0 software pack-
age (SIMED, Cre´teil, France), as described (14). The rate
constants of the various disposition phases and the AUC (ex-
trapolated to infinity) were estimated with a weighted-least
squares method (weighting factor, 1/y) using the model, whereas
the total plasma clearance of CPT-11 was calculated by dividing
dose (expressed in mg base equivalents per squared meter of
body surface area) and the observed AUC. The Cmax values
were determined graphically (as observed values) in a log
concentration-time scattered plot. Metabolic ratios were calcu-
lated as defined (15) and included the relative extent of conver-
sion (REC) of CPT-11 to SN-38 (i.e., AUCSN-38/AUCCPT-11)
and the relative extent of glucuronidation (REG) of SN-38 (i.e.,
AUCSN-38G/AUCSN-38). The latter was also evaluated as a func-
tion of time after drug administration. The systemic SN-38
glucuronidation rate in individual patients was estimated by
calculation of the biliary index (BI) values (7), expressed as
AUCCPT-11 3 (AUCSN-38/AUCSN-38G). The relative hematolog-
ical toxicity, i.e., the percentage decrease in WBCs, was defined
as: % decrease 5 [(pretherapy value) 2 nadir value)/(pre-
therapy value)] 3 100%.
Statistical Considerations. All pharmacokinetic param-
eters are reported as mean 6 SD. Because multiple measure-
ments were performed at different times on the same patients,
comparisons between the sets of observations were based on
within-subject differences. Therefore, variation between sub-
jects, which is usually considerable, does not affect our ability to
distinguish differences between the sets of observations, which
here relate to CPT-11 courses given in the absence or presence
of neomycin. The effect of neomycin on CPT-11 pharmacoki-
netic parameters was assessed using a paired Student’s t test and
the 95% confidence limits for the mean difference after testing
for normality and heteroscedasticity. Similarly, the effect of
neomycin on CPT-11-induced diarrhea (scored on a four-point
scale according to NCI-CTC and treated as ordered-categorical
data) was evaluated using the Wilcoxon-matched pairs signed
rank sum test. All calculations were done using the NCSS 5.X
Series software package (J. L. Hintze, East Kaysville, UT;
1992). Statistical significance was considered to be reached
when P , 0.05, with a two-tailed distribution.
Results
Toxicity and Pharmacodynamics. Twenty patients en-
tered this study, of which 9 (45%) developed grade 2 diarrhea in
the first treatment course and received neomycin as cotreatment
in the second course. Two patients in this group were not
evaluable for toxicity and pharmacokinetics in the second
course; 1 patient went off study after the first course at his own
request, and 1 patient was not evaluable because of early death
unrelated to treatment. The seven evaluable patients had a
median age of 57 years (range, 49–71 years) and an Eastern
Cooperative Oncology Group performance status of 0–1, and all
patients had normal hematopoietic and liver functions (except
ASAT ,2 N in two patients) at the time of study entry. The
median clinical chemistry values included a total bilirubin level
of 9 mM (range, 7–11 mM); a serum creatinine level of 99 mM
(range, 72–106 mM); ASAT levels of 34 units/l (range, 17–83
units/l) and ALAT levels of 22 units/l (range, 6–38 units/l); a
total protein concentration of 79 g/dl (range, 69–87 g/dl); and a
serum albumin level of 45 g/dl (range, 38–51 g/dl). All seven
patients experienced a grade 2 diarrhea with a median duration
of 6 days (range, 5–8 days) in their first course. Of these seven
(evaluable) patients, five (71%, P 5 0.0326) did not experience
any diarrhea in the second treatment course, one experienced
diarrhea grade 1 (3 days), and one experienced diarrhea grade 3
(5 days) in the second course.
The relative hematological toxicity, i.e., the percentage
decrease in WBCs, was not significantly different between
courses with values of 64.4 6 26.2% and 43.5 6 34.7% in the
absence and presence of neomycin, respectively (mean differ-
ence, 20.9 6 5.38%; 95% confidence limits for the mean dif-
ference, 8.33–33.5; P 5 0.058). The occurrence and severity of
nausea or vomiting during treatment was comparable for both
courses (data not shown). Feces cultures taken during the first
and the second courses did not reveal neomycin-resistant mi-
croorganisms nor any overgrowth of pathogenic microorgan-
isms. Cultures on infectious bacteria and toxins as mentioned
above remained negative throughout treatment.
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CPT-11 Pharmacokinetics. Plasma pharmacokinetics
of CPT-11 and its metabolites were evaluated during both the
first and second course (with neomycin) in all seven patients
(Table 1). The plasma concentration-time profiles of SN-38
after CPT-11 treatment were very similar for all patients studied
(Fig. 1). Administration of neomycin did not significantly alter
the AUC of CPT-11 and of the active compound SN-38, as
depicted in Fig. 2, A and B, and Table 1. Only the peak levels of
SN-38G were significantly lower in the second course (Fig. 2C),
but this did not alter the overall exposure to this metabolite.
Neomycin levels in urine were very low in all patients (range,
0.72–7.27 mg/ml; interpatient variability, 58 6 18%), indicating
no relevant absorption of the drug.
Fecal b-glucuronidase activity in the first course was sig-
nificantly higher than in the neomycin cotreatment course (Fig.
3A), compatible with the elimination of the intestinal microflora
by neomycin. Consequently, the fecal SN-38G:SN-38 ratio was
3-fold higher in the second course (Fig. 3B).
Discussion
In the current study, we obtained both clinical and phar-
macokinetic data in humans that increase our insight into the
pathogenesis and prevention of CPT-11-induced delayed-type
diarrhea. It has been shown previously that b-glucuronidase
activity derived from the intestinal microflora is able to hydro-
lyze biliary secreted SN-38G to the active compound SN-38 (8,
14). SN-38 can cause histological damage to the colon with
minimal damage to the small bowel, as was observed in a rat
model and as is believed to be the main course for the occur-
rence of CPT-11-induced delayed type diarrhea (8). Our present
results indicate that b-glucuronidase activity can be inhibited by
eliminating the microorganisms by administration of the (poorly
absorbed) aminoglycoside antibiotic neomycin, without any
signs of negative effects concerning bacterial overgrowth, tox-
ins, or neomycin resistance.
Because SN-38 is considered the active compound of
CPT-11 treatment, it is of the utmost importance that plasma
SN-38 pharmacokinetics are not altered by cotreatment with
neomycin. Because SN-38 is subject to enterohepatic recircula-
tion (13), suppressing intestinal b-glucuronidase activity could
potentially influence plasma pharmacokinetics. In this study, we
have shown that influencing b-glucuronidase activity by co-
treatment with neomycin in patients does not alter the plasma
SN-38 pharmacokinetics nor CPT-11 plasma disposition. The
paradox between the enterohepatic recirculation of SN-38 and
the lack of relationship of fecal b-glucuronidase activity with
SN-38 pharmacokinetics is presumably caused by the lack of
enzyme activity in the luminal contents of the entire small
intestine, where reabsorption of drug is most likely to occur
(13). However, we did find a minor but significant decline in the
peak levels of SN-38G. Although the total CPT-11 metabolism
has still not been completely elucidated, this particular alteration
might be explained by an up-regulation of serum b-glucuroni-
dase activity after repeated exposure to CPT-11, as has been
described earlier in a rat model (16), rather than by the coad-
ministration of neomycin. The earlier reported correlation be-
tween systemic glucuronidation and the incidence of diarrhea as
expressed in the biliary index (7) could not be found in our
patient population nor in a larger previous study (17). In con-
trast, we found unaltered biliary indices with and without neo-
mycin cotreatment (Table 1), with complete disappearance of
diarrhea after neomycin coadministration in five of seven pa-
tients. This is in keeping with the postulated concept regarding
the mechanism of CPT-11-induced diarrhea, being a direct local
Table 1 Pharmacokinetic variables of 350 mg/m2 i.v. CPT-11 for seven patients in the absence (course 1) and presence (course 2) of oral
neomycina
Course 1 Course 2 95% C.L. (d) Pb
CPT-11
Cmax (mM) 7.67 6 1.90 7.62 6 1.72 21.07 to 1.19 0.90
T1/2(z) (h) 12.9 6 3.40 13.4 6 5.34 25.99 to 4.92 0.81
AUC0–‘ (mM z h) 41.0 6 15.6 45.1 6 20.3 211.8 to 3.52 0.22
CL (l/h/m2) 15.8 6 3.79 14.8 6 4.42 21.88 to 3.74 0.44
Vss (l/m2) 137 6 36.4 141 6 48.9 231.8 to 22.5 0.68
MRT (h) 9.70 6 2.38 10.6 6 2.76 22.79 to 1.02 0.29
SN-38
Cmax (mM) 0.223 6 0.168 0.161 6 0.093 20.081 to 0.161 0.43
T1/2(z) (h) 46.7 6 6.72 41.9 6 3.86 24.92 to 14.4 0.25
AUC0–‘ (mM z h) 1.65 6 1.24 1.64 6 1.20 20.143 to 0.183 0.75
REC (3 102) 2.98 6 2.73 2.58 6 2.03 20.782 to 1.70 0.36
SN-38G
Cmax (mM) 0.414 6 0.128 0.290 6 0.072 0.035 to 0.211 0.016
T1/2(z) (h) 33.5 6 9.11 36.9 6 7.69 210.1 to 3.29 0.23
AUC0–‘ (mM z h) 8.92 6 4.45 8.66 6 3.38 21.39 to 1.90 0.69
REG 5.34 6 2.82 5.14 6 2.53 20.476 to 0.884 0.45
BI 3390 6 2360 3880 6 2830 21260 to 295 0.16
a Data are expressed as mean values 6 SD.
b Two-tailed paired Student’s t test. 95% C.L. (d), 95% confidence limits for the mean difference; Cmax, peak plasma concentration; T1/2(z),
apparent half-life of the terminal disposition phase; AUC0–‘, area under the plasma concentration-time curve extrapolated to infinity; CL, total plasma
clearance; Vss, volume of distribution at steady-state; MRT, mean residence time; REC, relative extent of conversion of CPT-11 into SN-38
(i.e., AUCSN-38/AUCCPT-11); REG, relative extent of glucuronidation of SN-38 into SN-38G (i.e., AUCSN-38G/AUCSN-38); BI, biliary index [i.e.,
AUCCPT-11 3 (AUCSN-38/AUCSN-38G)].
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toxic effect of the active compound SN-38, and sheds light on an
important mechanistic aspect of the role of bacterial b-glucu-
ronidases in its etiology.
In contrast to earlier data from Phase III studies reporting
on CPT-11-induced delayed-type diarrhea (3), only 45% of the
patients enrolled in the current study developed diarrhea in the
first course of chemotherapy, and this diarrhea was never worse
than grade 2. This low frequency of diarrhea could be either
attributable to patient selection or to the small number of pa-
tients enrolled in this study. Importantly, however, from the
seven patients evaluable for study purposes, five did not expe-
rience any diarrhea after coadministration of neomycin, whereas
additionally in one other patient the grade of diarrhea reduced
from grade 2 to 1, and this diarrhea lasted for only 3 days. Only
one patient experienced a more severe diarrhea with coadmin-
istration of neomycin.
We selected the poorly absorbed aminoglycoside antibiotic
neomycin because of its broad antimicrobial spectrum as well as
its local gastrointestinal disposition. Indeed, neomycin concen-
trations in the urine were very low after its administration,
indicating that no substantial drug absorption took place. As
with many antibiotics, treatment with this agent can cause
diarrhea and malabsorption, which could have been the case in
the one patient who experienced grade 3 diarrhea in the second
course. This side effect is usually seen only with chronic ad-
ministration in high ($12 g/day) dosage regimens (18). Because
neomycin can induce diarrhea, largely depending on dosage and
duration of treatment, with no data available on b-glucuronidase
activity compared with lengths of treatment, these are currently
the subject of investigation by us.
In theory, other antibiotics could also have been used in the
treatment of CPT-11-induced delayed-type diarrhea, but clearly
a nonresorbable drug is to be preferred. It would be even more
attractive to use an agent that specifically inhibits the microbial
b-glucuronidase activity. Hange-shasin-to (also referred to as
TJ14), a herbal medicine that contains the b-glucuronidase
inhibitor baicalin, has been described recently to be a potent
inhibitor of delayed-type diarrhea caused by CPT-11 in a rat
model (19) as well as in humans (20). Unfortunately, there is yet
no information on possible changes in plasma b-glucuronidase
activity because of this agent. Neither are there data whether and
how this agent influences plasma CPT-11 and SN-38 disposi-
tion, information of vital importance considering antitumor ac-
tivity.
In conclusion, cotreatment of CPT-11 with neomycin ef-
fectively decreases fecal b-glucuronidase activity and conse-
quently decreases enteral SN-38 concentrations without altering
the plasma pharmacokinetics and metabolic profiles of both
CPT-11 and SN-38. This therapy could ultimately lead to de-
Fig. 2 Plasma concentration-time profiles of CPT-11 (A), SN-38 (B),
and SN-38G (C) in patients treated with 350 mg/m2 i.v. CPT-11 in the
absence (E) and presence (F) of oral neomycin. Data are displayed as
mean values of seven patients (E, F); bars, SD. Note the different scales
used for the X axis and Y axis in the three figures.
Fig. 3 Fecal b-glucuronidase activity (A) and fecal SN-38G/SN-38
concentration ratios (B) in patients treated with 350 mg/m2 i.v. CPT-11
in the absence and presence of oral neomycin. Data are displayed as
mean values of seven patients; bars, SD.
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creased CPT-11-induced delayed-type diarrhea. A large ran-
domized clinical trial of CPT-11 chemotherapy with or without
prophylactic neomycin administration to patients is presently
being conducted to confirm the present findings.
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